Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
204
datasets available to search
ShareScore release 0.9.0
Dataset results
204 results for “Drug-resistance”
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
ClinicalTrials.gov study NCT06388707. IPD Sharing: NO. Countries: 1. Publications: 3.
Impact of Thermocoagulation During Invasive EEG Monitoring in Children With Focal Drug-resistant Epilepsies
ClinicalTrials.gov study NCT02886650. IPD Sharing: Not stated. Countries: 1. Publications: 0.
TDCs to Treat Drug-resistant Epilepsy
ClinicalTrials.gov study NCT05825274. IPD Sharing: YES. Countries: 1. Publications: 3.
Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression
ClinicalTrials.gov study NCT06232291. IPD Sharing: YES. Countries: 1. Publications: 1.
Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy
ClinicalTrials.gov study NCT02304029. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Optimum Treatment for Drug-Resistant Hypertension
ClinicalTrials.gov study NCT02369081. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Artificial Inteligent for Diagnosing Drug-Resistant Tuberculosis
ClinicalTrials.gov study NCT04208789. IPD Sharing: UNDECIDED. Countries: 1. Publications: 19.
Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation
ClinicalTrials.gov study NCT01713270. IPD Sharing: Not stated. Countries: 1. Publications: 1.
KETOMIGRAINE: Ketogenic Diet in Drug-resistant Chronic Migraineurs
ClinicalTrials.gov study NCT05313503. IPD Sharing: NO. Countries: 1. Publications: 3.
Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epilepsy
ClinicalTrials.gov study NCT04782869. IPD Sharing: NO. Countries: 1. Publications: 0.
Global Consortium for Drug-resistant Tuberculosis Diagnostics
ClinicalTrials.gov study NCT02170441. IPD Sharing: Not stated. Countries: 3. Publications: 7.
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
ClinicalTrials.gov study NCT03827811. IPD Sharing: UNDECIDED. Countries: 6. Publications: 43.
Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria
ClinicalTrials.gov study NCT02328183. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients
ClinicalTrials.gov study NCT05958069. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study
ClinicalTrials.gov study NCT02731300. IPD Sharing: NO. Countries: 0. Publications: 1.
Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation
ClinicalTrials.gov study NCT02164435. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Delays and loss to follow up before treatment of drug-resistant TB following implementation of Xpert MTB/RIF in South Africa: a retrospective cohort study
Open the record for dataset details and reuse information.
Transformable nano-antibiotics for mechanotherapy and immune activation against drug-resistant Gram-negative bacteria
Open the record for dataset details and reuse information.
Data from: The impact of within-host ecology on the fitness of a drug-resistant parasite
Background and objectives: The rate of evolution of drug resistance depends on the fitness of resistant pathogens. The fitness of resistant pathogens is reduced by competition with sensitive pathogens in untreated hosts and so enhanced by competitive release in drug-treated hosts. We set out to estimate the magnitude of those effects on a variety of fitness measures, hypothesizing that competitive suppression and competitive release would have larger impacts when resistance was rarer to begin with. Methodology: We infected mice with varying densities of drug-resistant Plasmodium chabaudi malaria parasites in a fixed density of drug-sensitive parasites and followed infection dynamics using strain-specific quantitative PCR. Results: Competition with susceptible parasites reduced the absolute fitness of resistant parasites by 50-100%. Drug treatment increased the absolute fitness from 2- to >10 000-fold. The ecological context and choice of fitness measure was responsible for the wide variation in those estimates. Initial population growth rates poorly predicted parasite abundance and transmission probabilities. Conclusions and implications: (i) The sensitivity of estimates of pathogen fitness to ecological context and choice of fitness measure make it difficult to derive field-relevant estimates of the fitness costs and benefits of resistance from experimental settings. (ii) Competitive suppression can be a key force preventing resistance from emerging when it is rare, as it is when it first arises. (iii) Drug treatment profoundly affects the fitness of resistance. Resistance evolution could be slowed by developing drug use policies that consider in-host competition.
Data from: The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection
Malaria infections normally consist of more than one clonally-replicating lineage. Within-host interactions between sensitive and resistant parasites can have profound effects on the evolution of drug resistance. Here, using the Plasmodium chabaudi mouse malaria model, we ask whether the costs and benefits of resistance are affected by the number of co-infecting strains competing with a resistant clone. We found strong competitive suppression of resistant parasites in untreated infections and marked competitive release following treatment. The magnitude of competitive suppression depended on competitor identity. However, there was no overall effect of the diversity of susceptible parasites on the extent of competitive suppression or release. If these findings generalize, then transmission intensity will impact on resistance evolution because of its effect on the frequency of mixed infections, not because of its effect on the distribution of clones per host. This would greatly simplify the computational problems of adequately capturing within-host ecology in models of drug resistance evolution in malaria.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.